Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Center, Multiple-Dose Study to Assess the Safety and Pharmacokinetics of ZYN002 Administered as a Transdermal Gel to Healthy Subjects

Next Previous
X
Search
Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Single-Center, Multiple-Dose Study to Assess the Safety and Pharmacokinetics of ZYN002 Administered as a Transdermal Gel to Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions
  • Sponsors Zynerba Pharmaceuticals

    • Most Recent Events

    • 05 Dec 2016 According to a Zynerba Pharmaceuticals media release, results from this study reported at the 70th Annual Meeting of the American Epilepsy Society (AES).
    • 05 Dec 2016 Results published in the Zynerba Pharmaceuticals Media Release.
    • 26 Sep 2016 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top